Abivax Financials - Benzinga

Abivax SA

ABVXNASDAQ

Trade with Public

Trade with Public

$118.64

2.692.32%

At close: Sep 11, 5:00 PM EST

$118.00

-0.64-0.54%

After Hours: Sep 11, 4:12 PM EST

Earnings: H1 2026 Earnings in 7 days from now on Mon Sep 21st, after the market close

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Options Stock Report

Abivax Financials

Abivax (ABVX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Abivax Holds Cash, Cash Equivalents And Short-Term Investments Of €491.6 Million As Of March 31, 2026; Providing A Projected Cash Runway Into Q4 2027 Based On Current Operating Assumptions

Benzinga Newsdesk

Earnings Scheduled For March 23, 2026

Benzinga Insights

PRO
Abivax Outlines 2026 Outlook Highlighting Phase 3 ABTECT-UC Topline Data Expected In Late Q2 2026 With Subsequent U.S. Regulatory Filing PlanFor Late-2026; ENHANCE-CD Phase 2b Induction Trial Of Obefazimod In Moderate-To-Severely Active Crohn's Disease Ongoing With Induction Results Expected Late 2026

Abivax Provides 2026 Corporate OutlookNew market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD

Benzinga Newsdesk

PRO
Abivax Presents Q3 2025 Financial Results; Cash And Cash Equivalents Of €589.7 Million, As Of September 30, 2025, With A Cash Runway Into Q4 2027

Benzinga Newsdesk

Earnings Scheduled For August 11, 2025

Benzinga Insights

Earnings Outlook For Abivax

Benzinga Insights